Funding agencies: This work was supported by a fellowship award (to T.D.H.) from the Bachmann-Strauss Dystonia & Parkinson Foundation, New York, NY.
Version of Record online: 2 JUN 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 9, pages 1677–1683, 1 August 2011
How to Cite
Hälbig, T. D., Assuras, S., Creighton, J., Borod, J. C., Tse, W., Frisina, P. G., Voustianiouk, A., Gracies, J.-M. and Olanow, C. W. (2011), Differential role of dopamine in emotional attention and memory: Evidence from Parkinson's disease. Mov. Disord., 26: 1677–1683. doi: 10.1002/mds.23728
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 9 AUG 2011
- Version of Record online: 2 JUN 2011
- Manuscript Accepted: 1 MAR 2011
- Manuscript Revised: 6 JAN 2011
- Manuscript Received: 9 AUG 2010
- emotional processing;
- basal ganglia;
- Parkinson's disease
Consistent with the hypothesis that dopamine is implicated in the processing of salient stimuli relevant to the modification of various behavioral responses, Parkinson's disease is associated with emotional blunting. To address the hypothesis that emotional attention and memory are modulated by dopaminergic neurotransmission in Parkinson's disease, we assessed 15 nondemented patients with Parkinson's disease while on and off dopaminergic medication and 15 age-matched healthy controls. Visual stimuli were presented, and recognition was used to assess emotional memory. Response latency was used as a measure of emotional attention modulation. Stimuli were varied based on valence (pleasant, neutral, and unpleasant) and arousal (high and low) dimensions. Controls had significantly better memory for positive than negative stimuli, whereas patients with Parkinson's disease tested off medication had significantly better memory for negative than positive items. This negativity bias was lost when they were tested while on dopaminergic medication. Reaction times in patients with Parkinson's disease off medication were longer than in healthy controls and, paradoxically, were even longer when on medication. Further, although both healthy controls and patients with Parkinson's disease in the “off” state had arousal-induced prolongation of reaction time, this effect was not seen in patients with Parkinson's disease on medication. These data indicate that dopaminergic neurotransmission is implicated in emotional memory and attention and suggest that dopamine mediates emotional memory via the valence dimension and emotional attention via arousal. Furthermore, our findings suggest that emotional changes in Parkinson's disease result from the effects of both the disease process and dopaminergic treatment. © 2011 Movement Disorder Society